Washington D.C., Feb. 18 -- : An investigator from Dana-Farber Cancer Institute now says that a combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer. The investigator made the claims after the release of results from a phase 3 clinical trial.
The study found that patients who received the immunotherapy drug avelumab plus axitinib, a targeted agent, had a significant advantage in progression-free survival compared with those who received sunitinib (Sutent), a targeted drug that has been a standard treatment for advanced clear cell renal cell carcinoma - the most common form of kidney cancer.
Speaking about it, senior and co-corresponding...